Purchase Order 75N92025P00398
- Not listed
- This federal contract award, valued at $63,000, was issued by the National Institutes of Health (NIH) Clinical Center to Terumo BCT, Inc., a foreign-owned, for-profit manufacturer of medical devices and provider of blood and cell technology services. The contract is a firm fixed-price purchase order with a completion date of June 4, 2018. Terumo BCT, operating as the Terumo Bct, Inc. Division and doing business as Caridianbct, provides a wide range of specialized products and services to federal...
- This award to Terumo BCT, Inc. is a firm fixed-price purchase order from the Department of Health and Human Services National Institutes of Health Clinical Center. The contract has a potential value of $119,154.00 and is not set aside for any particular business category. Terumo BCT, Inc. is a manufacturer of medical devices and provider of services related to blood and cell technologies, including equipment, consumables, and maintenance support for blood collection, processing, storage, and...
- Terumo BCT, Inc., doing business as CaridianBCT, has been awarded a firm fixed-price purchase order valued at twenty-five thousand two hundred ninety-eight dollars and twenty-six cents ($25,298.26) by the Department of Health and Human Services' National Institutes of Health Clinical Center. The contract term runs from October 31, 2023 through December 15, 2023. Performance will take place in Lakewood, Colorado. As the prime contractor, Terumo BCT will provide unspecified products or services to...
- Terumo BCT Inc., a Colorado-based manufacturer of advanced blood and cell technology medical devices, was awarded a $19,039.92 firm fixed-price purchase order by the National Institute of Allergy and Infectious Diseases (NIAID) on July 9, 2018. The contract represents an option exercise with a performance location in Denver, Colorado, and carries an ultimate completion date of July 8, 2021. This award was not designated as a set-aside contract. Terumo BCT, operating under the doing-business-as...
- This federal contract award was made by the U.S. Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse to Terumo BCT, Inc., a manufacturer of medical devices and services related to blood and cell technologies. The $149,162 firm fixed-price purchase order contract was awarded on August 11, 2017 with a completion date of October 11, 2017, and did not use a small business set-aside. Terumo BCT has provided a range of blood management products...
- The Department of Health and Human Services National Institutes of Health Clinical Center awarded a $23,042 purchase order to Terumo BCT Inc., doing business as Caridianbct, for TSCD II sterile tubing welders. The firm fixed price contract runs from December 5, 2023 to February 2, 2024 and will provide sterile tubing welders to support NIH Clinical Center programs. Terumo BCT will deliver the requested medical devices from its Lakewood, Colorado facility as the prime contractor. No...
- This is a firm fixed-price purchase order contract awarded by the Department of Health and Human Services National Institutes of Health Clinical Center to Terumo BCT, Inc., a foreign-owned, for-profit manufacturer of medical devices and blood management products and services. The contract, valued at $115,350.00, is for the provision of blood bag systems, tubing sets, sterile tubing welders, cell washing equipment, preventative maintenance services, and other accessories used in apheresis, cell...
- This federal contract award is to Terumo BCT, Inc., a manufacturer of medical devices and provider of services related to blood and cell technologies. The $260,000.00 firm fixed price purchase order was issued by the Department of Health and Human Services, National Institutes of Health Clinical Center. The contract provides Terumo BCT's blood bag systems, tubing sets, sterile tubing welders, cell washing equipment, preventative maintenance services, and other accessories used in apheresis, cell...
- This is a firm fixed-price purchase order awarded by the National Institutes of Health (NIH) Clinical Center to Terumo BCT Inc., a foreign-owned, for-profit manufacturer of medical devices and provider of blood and cell technology services. The $8,097.28 contract provides for preventative maintenance of two COBE 2991 cell processors at the NIH facility in Bethesda, Maryland. The contract has a period of performance through August 25, 2028. This award does not have a small business set-aside...
- This federal contract was awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to Terumo BCT Inc., a foreign-owned, for-profit manufacturer of medical devices and provider of services related to blood and cell technologies. The $195,000.00 firm-fixed-price purchase order was for the delivery of 3-blood cell separators, with a completion date of September 29, 2017. Terumo BCT has a history of providing a range of blood management products...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $19,900.47 firm fixed-price purchase order to Terumo BCT Inc. (doing business as Caridianbct Inc.) on September 22, 2025, with an ultimate completion date of November 22, 2025. The contract supports the NIH NHLBI In-Vivo Gene Therapy Core's operational requirements by supplying a Terumo tube sealer, a specialized medical device used to seal tubes and bags containing cell products for sterile storage. This no set-aside contract was awarded without small business designation considerations. Terumo BCT Inc., a foreign-owned medical device manufacturer headquartered in Lakewood, Colorado, specializes in advanced blood and cell technology services. The company has established a track record as a federal contractor providing sophisticated medical equipment and consumables to health-focused agencies, including the NIH, Department of Defense, and Department of Veterans Affairs. The tube sealer delivery under this purchase order aligns with the company's core expertise in cellular therapy technologies and supports the NHLBI's gene therapy research infrastructure at the in-vivo core facility.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $19.9k | 9/23/25 |